Peptide Comparison
CapromorelinvsCJC-1295 (No DAC)
An oral ghrelin agonist originally developed by Pfizer that stimulates growth hormone and appetite. FDA-approved for veterinary use (Entyce and Elura) and investigated in human trials for age-related muscle wasting and appetite support.
A modified growth hormone-releasing hormone that boosts your body's natural GH pulses for better recovery, deeper sleep, and improved body composition.
At a Glance
Quick
comparison
Dose Range
Capromorelin
3–30 mg
CJC-1295 (No DAC)
100–300 mcg
Frequency
Capromorelin
Once daily
CJC-1295 (No DAC)
Once daily
Administration
Capromorelin
Oral (capsule or tablet)
CJC-1295 (No DAC)
Subcutaneous injection
Cycle Length
Capromorelin
4-6 weeks
CJC-1295 (No DAC)
8-12 weeks
Onset Speed
Capromorelin
Moderate (1-2 weeks)
CJC-1295 (No DAC)
Moderate (1-2 weeks)
Evidence Level
Capromorelin
Moderate human trials (Phase 1-2)
CJC-1295 (No DAC)
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
GH & IGF-1 Stimulation
Physical Function
Oral Convenience
GH Stimulation
Sleep Quality
Recovery Support
Technical Data
Compound
specifications
Capromorelin
Molecular Formula
C28H35N5O4
Molecular Weight
505.6 g/mol
Half-Life
1-2.4 hours in humans
Bioavailability
Good oral bioavailability
CAS Number
193273-66-4
CJC-1295 (No DAC)
Molecular Formula
C152H252N44O42
Molecular Weight
3367.9 g/mol
Half-Life
30 minutes to 2 hours
Bioavailability
~100% (subcutaneous)
CAS Number
863288-34-0
Protocols
Dosing
tiers
Capromorelin
CJC-1295 (No DAC)
Applications
Best
suited for
Capromorelin
Age-Related Muscle Wasting
Capromorelin showed significant improvements in physical function — including tandem walk and stair climb — in elderly adults, making it a strong candidate for combating sarcopenia.
Appetite Stimulation
As an FDA-approved veterinary appetite stimulant, capromorelin has extensive real-world evidence for boosting food intake and body weight in mammals.
Growth Hormone Research
One of the best-studied oral ghrelin agonists with human Phase 2 data, offering researchers a well-characterized tool for studying GH/IGF-1 pathways.
CJC-1295 (No DAC)
Natural Growth Hormone Optimization
Perfect for those wanting to boost their body's own GH production rather than using synthetic growth hormone. Mimics the natural pulsatile release pattern your pituitary uses.
Workout Recovery and Muscle Building
Athletes and fitness enthusiasts use it to accelerate recovery between training sessions, support lean muscle development, and reduce body fat over time.
Sleep Quality Enhancement
Because GH is naturally released during deep sleep, many users report dramatically improved sleep quality with more vivid dreams and feeling more refreshed upon waking.
Anti-Aging and Vitality
As GH levels decline with age, CJC-1295 helps restore more youthful hormone patterns, potentially improving skin quality, energy levels, and overall well-being.
Synergistic Peptide Stacking
Designed to work hand-in-hand with GHRPs like Ipamorelin. When combined, these peptides amplify each other's effects for significantly greater GH release than either alone.
Safety Profile
Side
effects
Capromorelin
Common
- Appetite stimulation
- Fluid retention and weight gain
Uncommon
- Joint and muscle aches
- Fatigue or lethargy
- Peripheral edema (swelling)
Serious
- Hyperglycemia
CJC-1295 (No DAC)
Common
- Injection site reactions
- Flushing or warmth
- Water retention
- Increased appetite
Uncommon
- Tingling or numbness
- Headache
Serious
- Allergic reaction
Research Status
Safety
& evidence
Capromorelin
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
FDA approved for this use
Safety Overview
Capromorelin was generally well-tolerated in Phase 2 human trials involving nearly 400 elderly participants. Most side effects were mild to moderate. Its FDA-approved veterinary use provides additional long-term safety data in mammalian species.
Contraindications
- xActive cancer or history of cancer (GH may stimulate growth)
- xUncontrolled diabetes or severe metabolic disorders
- xSevere liver or kidney disease
- xPregnancy and lactation
CJC-1295 (No DAC)
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
CJC-1295 without DAC has been studied in Phase 1-2 human clinical trials with a favorable safety profile. The most common side effects are mild and include injection site reactions and temporary flushing. Because it stimulates natural GH release rather than providing exogenous GH, it maintains the body's feedback mechanisms.
Contraindications
- xActive cancer or history of cancer
- xPregnancy or breastfeeding
- xPituitary tumors or disorders
- xHypersensitivity to GHRH analogs
- xDiabetic retinopathy
Decision Guide
Which is
right for you?
Choose Capromorelin if...
- Stimulating growth hormone production in elderly adults
- Supporting appetite and weight gain in wasting conditions
- Improving muscle mass and physical performance
- Anti-aging and longevity optimization
Choose CJC-1295 (No DAC) if...
- Increasing natural growth hormone levels
- Building lean muscle mass
- Improving sleep quality
- Enhancing workout recovery